Bamlanivimab

Bamlanivimab Was Designed To Block The SARS-CoV-2 Virus From Entering And Infecting Human Cells. Eli Lilly Reported In An early Analysis that Patients With Mild To Moderate COVID-19 Who Got Bamlanivimab Were Less Likely To Be Hospitalized Compared To Those Who Did Not Get It (2% Were Hospitalized Vs. 6%, Respectively). They Tested Three Different Doses. By Day 11, The 2,800 Mg Dose Had Helped Clear The Virus Faster, But The Lower And Higher Doses Did Not — This Finding Likely Is Not A Good Indicator Of Health Though Since Patients Who Got A Placebo Also Were Able To Clear Some Of The Virus On Their Own